Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Growth in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 31st total of 3,200 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Trading Up 2.5 %

Shares of NASDAQ ANL traded up $0.05 during trading hours on Thursday, hitting $2.10. The stock had a trading volume of 645 shares, compared to its average volume of 12,107. The firm’s 50-day moving average price is $2.21 and its two-hundred day moving average price is $2.48. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.